In addition to the established cardiovascular benefits of SGLT2 inhibitors, the updated data support the use of SGLT2 inhibitors to modify the risk of CKD progression and AKD, not only in patients with type 2 DM at high cardiovascular risk but also in patients with CKD or heart failure irrespective of diabetes status, primary kidney disease, or kidney function 49, 50. Here, SLC5A2 is linked to chronic kidney disease.